ETANA SUPPORTS INNOVATIVE KIDNEY DISEASE TREATMENT IN INDONESIA

Jakarta, March 14, 2025 – In commemoration of World Kidney Day, Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to supporting innovation in kidney disease treatment in Indonesia. As a biotechnology company, Etana actively contributes to providing high-quality and affordable medicines for patients, especially those suffering from kidney disease. 

“One of the company’s main focuses is to improve access to quality medicines, including Erythropoietin Alfa, which is widely used by dialysis patients. We have locally produced, high-quality and affordable Erythropoietin Alfa. Moving forward, we aim to introduce more kidney-related healthcare products that are manufactured locally,” said Randy Stevia, Business Development Therapeutic Director of Etana.

Furthermore, Etana is currently developing the next generation of medicine—long-acting Erythropoietin—which only needs to be injected once every one to two weeks, making it more convenient for patients.

To increase access to treatment for kidney patients, Randy added, Etana is collaborating with the government to include its medicines in the e-catalogue system, enabling BPJS patients to access them through the National Health Insurance (JKN) program.

Etana has also partnered with health organizations and patient communities such as the Indonesian Dialysis Patients Community (KPCDI) to educate and support patients in accessing better treatment options.

“Together with KPCDI, we regularly conduct educational programs for kidney patients. This is part of our strategy to strengthen our portfolio of essential medications needed by kidney patients,” Randy explained.

“The biggest challenge for kidney failure patients in Indonesia is not only the treatment itself but also access to essential medications. Many patients still struggle to obtain drugs such as Erythropoietin and calcium phosphate supplements, which are crucial for maintaining their quality of life. That’s why collaboration with industry players like Etana is vital to improving the availability of these medicines. Together with Etana, KPCDI often organizes health education activities, covering promotive, preventive, curative, and rehabilitative aspects,” said Tony Samosir, Chairman of KPCDI.

“We hope the government will take more serious action to improve the accessibility of medicines and healthcare services for kidney failure patients in order to enhance their quality of life and healthcare,” Tony concluded.

Etana plans to expand its treatment portfolio to support kidney patients while also strengthening public health education. With a spirit of innovation and collaboration, Etana is committed to continuously advancing kidney disease treatment in Indonesia.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.